Lexicon Pharma (LXRX) Posts Q3 Loss of $0.14
LXRX Hot Sheet
Revenue Growth %: -73.6%Financial Fact:
Collaborative research: 152K
Today's EPS Names:
TARO, BRLI, TLB, More
Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) reports Q3 loss of $0.14, 3 cents better than the analyst estimate of ($0.17). Revenue for the quarter was $2.13 million, which compares to the estimate of $1.63 million.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Signet Jewelers (SIG) Tops Q1 EPS by 5c; Guides Q2 Below the Street
- Tiffany & Co. (TIF) Misses Q1 EPS Views; Lowers FY12 EPS, Revs Growth Outlook
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
